Last reviewed · How we verify
RETIN-A® Cream
At a glance
| Generic name | RETIN-A® Cream |
|---|---|
| Also known as | Tretinoin |
| Sponsor | Sun Pharmaceutical Industries, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Secretome TGF Beta 3 (NA)
- The Relationship Between Microbioma Balance and Acne Vulgaris as a New Acne Treatment (PHASE2)
- Clinical Trial to Compare Oral Isotretinoin to Standard of Care in Moderate Acne Skin of Color Patients (PHASE3)
- Development of Products Based on Secretom From Stem Cell Conditioned Medium for Melasma Therapy (NA)
- Treatment w/ Tri-Luma® Cream & Intense Pulsed Light (IPL) vs a Mild Inactive Control Cream & Intense Pulsed Light (IPL) in Melasma (PHASE4)
- Adapalene Gel 0.3% Versus Tretinoin 0.05% Emollient Cream for Treatment of Photodamage (PHASE3)
- Efficacy and Safety of Therapy With Tri-Luma® Cream in Sequence With Glycolic Acid Peels for Melasma (PHASE4)
- A Study Comparing Tretinoin Cream 0.025% and RETIN-A® Cream 0.025% in the Treatment of Acne Vulgaris (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RETIN-A® Cream CI brief — competitive landscape report
- RETIN-A® Cream updates RSS · CI watch RSS
- Sun Pharmaceutical Industries, Inc. portfolio CI